SG11202000105QA - Anti-cd166 antibodies and uses thereof - Google Patents
Anti-cd166 antibodies and uses thereofInfo
- Publication number
- SG11202000105QA SG11202000105QA SG11202000105QA SG11202000105QA SG11202000105QA SG 11202000105Q A SG11202000105Q A SG 11202000105QA SG 11202000105Q A SG11202000105Q A SG 11202000105QA SG 11202000105Q A SG11202000105Q A SG 11202000105QA SG 11202000105Q A SG11202000105Q A SG 11202000105QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- binding
- antibody
- suite
- california
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
40 -20 -10 6 35% 34 23 (12) INTERNATIONAL APPLICATION PUBLISHED (19) World Intellectual Property Organization International Bureau UNDER THE PATENT COOPERATION TREATY (PCT) IiiiionolivivivillEviiliololoillEvivivEmionvitiovois (10) International Publication Number WO 2019/014586 Al PCT (43) International Publication Date 17 January 2019 (17.01.2019) W I PO I Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (74) Agent: SHORE, David E. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2018/042074 (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,889 14 July 2017 (14.07.2017) US (71) Applicant: CYTOMX THERAPEUTICS, INC. [US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: DESNOYERS, Luc Roland; c/o CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). DUPAGE, Amy Grace; c/o CytomX Therapeutics, Inc., 151 Oyster (54) Title: ANTI-CD166 ANTIBODIES AND USES THEREOF Figure 13 Prevalence of CD166 Expression Across Metastatic Indications Number of cases scored -80+ cases Secondary Site 4 7 100-- — 178 % Strong /Mo dera te Exp ression 62 75 50 21 50 25 45 I I 51 71 25 0 e' S b 4 S cc` cc' 4' 9 + ..te s e\ t * 'b- A e t> e • 0 z 42<\" ci e ci° b 3 o <(% ,s 4 b *b c> „, t y , o t z e e e gf;. \ CP se e ( a. ckss s c> ez, kg ke as (20. €.> \ \ .tc` i e b 4, 0 'b. *A e e e e te b t e 43 43 ‘ 9 „ . 4 4 \ f t , c). cc• c° N t b- 2 b , e - - xe 16 t . 4 ‘ 3 Na .0 1-1 GC 71. 1-1 O 1-1 O (57) : The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capa- ble of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or anti- gen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (\"ICD\") of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypep- tide is useful in a method of detecting or treating a condition or disease. [Continued on next page] WO 2019/014586 Al IIIIIIIIIIIIHNEHICIII111111111111111111111111111111111111111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762532889P | 2017-07-14 | 2017-07-14 | |
PCT/US2018/042074 WO2019014586A1 (en) | 2017-07-14 | 2018-07-13 | Anti-cd166 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000105QA true SG11202000105QA (en) | 2020-02-27 |
Family
ID=63077998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000105QA SG11202000105QA (en) | 2017-07-14 | 2018-07-13 | Anti-cd166 antibodies and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (2) | US11220544B2 (en) |
EP (1) | EP3652210A1 (en) |
JP (1) | JP2020531045A (en) |
KR (1) | KR20200027971A (en) |
CN (1) | CN111133006A (en) |
AU (1) | AU2018300237A1 (en) |
BR (1) | BR112020000766A2 (en) |
CA (1) | CA3069804A1 (en) |
EA (1) | EA202090247A1 (en) |
IL (1) | IL271477A (en) |
MX (1) | MX2020000435A (en) |
SG (1) | SG11202000105QA (en) |
WO (1) | WO2019014586A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201792414A1 (en) | 2015-05-04 | 2018-06-29 | Сайтомкс Терапьютикс, Инк. | ANTIBODIES AGAINST CD166, ACTIVATED ANTIBODIES AGAINST CD166 AND METHODS OF THEIR APPLICATION |
JP2020531045A (en) | 2017-07-14 | 2020-11-05 | シートムエックス セラピューティクス,インコーポレイテッド | Anti-CD166 antibody and its use |
WO2019155086A1 (en) * | 2018-02-12 | 2019-08-15 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
CA3100018A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
JP7460609B2 (en) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス, インコーポレイテッド | Activable interleukin-2 polypeptides and methods of use thereof |
JP2022532217A (en) | 2019-05-14 | 2022-07-13 | ウェアウルフ セラピューティクス, インコーポレイテッド | Separation part and how to use it |
WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
WO2023183923A1 (en) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
KR100663319B1 (en) | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | A human antibody specific for the human 17-1A antigen and uses thereof |
WO1999011287A1 (en) | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
PE20011227A1 (en) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES |
US6719750B2 (en) | 2000-08-30 | 2004-04-13 | The Johns Hopkins University | Devices for intraocular drug delivery |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
ES2368387T5 (en) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Therapeutic and tolerance-inducing antibodies |
CN1662254A (en) | 2002-05-03 | 2005-08-31 | 雷文生物技术公司 | ALCAM and ALCAM modulators |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
BRPI0417959A (en) * | 2003-12-22 | 2007-03-27 | Glaxo Group Ltd | antibody or functional fragment thereof, pharmaceutical composition, method for treating or prophylaxis of stroke and other neurological disorders / disorders in a human, use of an anti-goat antibody, and methods for inhibiting neurodegeneration and / or promoting recovery function in a human patient, to promote axonal growth, to produce an antifungal antibody and to produce an intravenously administered pharmaceutical composition |
US20090306347A1 (en) | 2005-08-29 | 2009-12-10 | Japan Science And Technology Agency | Antibody produced using ostrich and method for production thereof |
US7582441B1 (en) * | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
JP5612247B2 (en) | 2005-11-29 | 2014-10-22 | 独立行政法人科学技術振興機構 | Monoclonal antibody against CD166 and production method thereof |
EP2078732B1 (en) | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
GB0705775D0 (en) | 2007-03-26 | 2007-05-02 | Affitech As | Product |
EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
JP2009055899A (en) * | 2007-08-07 | 2009-03-19 | Igaku Seibutsugaku Kenkyusho:Kk | Antibody with enhanced adcc activity and method for producing the same |
CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
EP2348052A3 (en) | 2007-09-17 | 2011-10-26 | The Regents of The University of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
RU2010138612A (en) * | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | HUMANIZED ANTIBODIES AGAINST C5aR |
WO2010074049A1 (en) * | 2008-12-22 | 2010-07-01 | 株式会社 未来創薬研究所 | Anti-hs6st2 antibody and use thereof |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
EP2419447B1 (en) * | 2009-04-17 | 2017-08-23 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
CN101948802A (en) * | 2010-08-31 | 2011-01-19 | 中国人民解放军第三军医大学第一附属医院 | Method for sorting human articular cartilage CD105+/CD166+ mesenchymal stem cells by using immunomagnetic beads |
CN104540518A (en) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
WO2014026136A2 (en) | 2012-08-10 | 2014-02-13 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
CA2894879A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
CN112162094A (en) | 2013-01-04 | 2021-01-01 | 西托姆克斯治疗公司 | Compositions and methods for detecting protease activity in biological systems |
CN116063479A (en) | 2013-06-04 | 2023-05-05 | 西托姆克斯治疗公司 | Compositions and methods for conjugating activatable antibodies |
EA201792414A1 (en) * | 2015-05-04 | 2018-06-29 | Сайтомкс Терапьютикс, Инк. | ANTIBODIES AGAINST CD166, ACTIVATED ANTIBODIES AGAINST CD166 AND METHODS OF THEIR APPLICATION |
WO2017015227A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating cd166-expressing cancer |
AU2016348342B2 (en) | 2015-11-04 | 2023-07-06 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN109311992B (en) | 2016-06-15 | 2022-10-18 | 克利夫兰临床基金会 | Novel anti-CD 6 antibodies for the treatment of T cell mediated diseases |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018071058A1 (en) | 2016-10-15 | 2018-04-19 | Baylor College Of Medicine | Platform for enhanced targeted cell delivery |
JP2020531045A (en) | 2017-07-14 | 2020-11-05 | シートムエックス セラピューティクス,インコーポレイテッド | Anti-CD166 antibody and its use |
BR112020004231A2 (en) | 2017-08-30 | 2020-09-08 | Cytomx Therapeutics, Inc. | activable anti-cd166 antibodies and methods of using them |
CN113260383A (en) | 2018-11-02 | 2021-08-13 | 西托姆克斯治疗公司 | Activatable anti-CD 166 antibodies and methods of use thereof |
-
2018
- 2018-07-13 JP JP2020523234A patent/JP2020531045A/en active Pending
- 2018-07-13 BR BR112020000766-8A patent/BR112020000766A2/en unknown
- 2018-07-13 US US16/630,975 patent/US11220544B2/en active Active
- 2018-07-13 EA EA202090247A patent/EA202090247A1/en unknown
- 2018-07-13 EP EP18749259.0A patent/EP3652210A1/en not_active Withdrawn
- 2018-07-13 AU AU2018300237A patent/AU2018300237A1/en not_active Abandoned
- 2018-07-13 MX MX2020000435A patent/MX2020000435A/en unknown
- 2018-07-13 SG SG11202000105QA patent/SG11202000105QA/en unknown
- 2018-07-13 CA CA3069804A patent/CA3069804A1/en active Pending
- 2018-07-13 WO PCT/US2018/042074 patent/WO2019014586A1/en unknown
- 2018-07-13 KR KR1020207003368A patent/KR20200027971A/en not_active Application Discontinuation
- 2018-07-13 CN CN201880059731.XA patent/CN111133006A/en active Pending
-
2019
- 2019-12-16 IL IL271477A patent/IL271477A/en unknown
-
2021
- 2021-11-09 US US17/522,189 patent/US20220242949A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020531045A (en) | 2020-11-05 |
CA3069804A1 (en) | 2019-01-17 |
MX2020000435A (en) | 2020-08-17 |
WO2019014586A1 (en) | 2019-01-17 |
EA202090247A1 (en) | 2020-05-12 |
KR20200027971A (en) | 2020-03-13 |
US20220242949A1 (en) | 2022-08-04 |
US11220544B2 (en) | 2022-01-11 |
US20200223919A1 (en) | 2020-07-16 |
CN111133006A (en) | 2020-05-08 |
EP3652210A1 (en) | 2020-05-20 |
AU2018300237A1 (en) | 2020-01-16 |
IL271477A (en) | 2020-01-30 |
BR112020000766A2 (en) | 2020-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909205YA (en) | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201907422RA (en) | Anti-tau antibodies and methods of use thereof | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof |